Pharma BD Deal Intelligence

Johnson & Johnson / Crucell N.V.

2010 · Acquisition/Merger · $2.4B · Complete

J&J reached agreement on October 6, 2010 to acquire remaining ~82% of Crucell for €24.75/share, valuing Crucell at ~€1.75B (~$2.4B). J&J had bought 18% in 2009. Crucell became Janssen Vaccines.

Did it work? Outcome assessment

Assessment window: 10yr post-close.

Key facts

• Announced Sep 17, 2010
• Closed Feb 22, 2011
• Deal value $2.4B
• Deal type Acquisition/Merger
• Therapeutic area Vaccines (pediatric combination); influenza
• Indications Vaccines (pediatric combination); influenza
• Key assets Quinvaxem; CR6261 broad-spectrum flu antibody
• Mechanism Vaccine and antibody platform (PER.C6, AdVac)

← Browse all deals  ·  How we score deals